What is OptimizeRx's cash & equivalents?

OptimizeRx (OPRX) reported cash & equivalents of $20.17M in Q1 2026.

How has OptimizeRx's cash & equivalents changed year-over-year?

OptimizeRx's cash & equivalents increased by 21.7% year-over-year, from $16.57M to $20.17M.

What is the long-term trend for OptimizeRx's cash & equivalents?

Over 5 years (2020 to 2025), OptimizeRx's cash & equivalents has grown at a 17.3% compound annual growth rate (CAGR), from $10.52M to $23.37M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

OptimizeRx OPRX Cash & Equivalents

Cash & Equivalents at other companies

Veeva SystemsVEEV

$1.9B-3.5%

DoximityDOCS

$219.18M+4.6%

GoodRx Holdings, Inc.GDRX

$235.71M-21.7%

PubMaticPUBM

$144.88M+42.3%

National Research CorporationNRC

$2.55M+1.8%

Fluent, Inc.FLNT

$10.3M+113%

Other financials

Income statement

See full

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

See full

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

See full

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

See full

Market cap$107.34M-54.1%

Enterprise value$110.88M-55.0%

P/E15.7×—

P/S1×-1.2×

Profitability

See full

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

See full

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OptimizeRx's cash & equivalents?: OptimizeRx (OPRX) reported cash & equivalents of $20.17M in Q1 2026.
How has OptimizeRx's cash & equivalents changed year-over-year?: OptimizeRx's cash & equivalents increased by 21.7% year-over-year, from $16.57M to $20.17M.
What is the long-term trend for OptimizeRx's cash & equivalents?: Over 5 years (2020 to 2025), OptimizeRx's cash & equivalents has grown at a 17.3% compound annual growth rate (CAGR), from $10.52M to $23.37M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.